BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 31009255)

  • 1. Selection of adjuvants for vaccines targeting specific pathogens.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular signatures of vaccine adjuvants.
    Olafsdottir T; Lindqvist M; Harandi AM
    Vaccine; 2015 Sep; 33(40):5302-7. PubMed ID: 25989447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.
    Tima HG; Huygen K; Romano M
    Expert Rev Vaccines; 2016 Nov; 15(11):1409-1420. PubMed ID: 27206681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccines: what do we want and how can we get it?
    Geeraedts F; Huckriede A
    Adv Exp Med Biol; 2011; 780():161-74. PubMed ID: 21842372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modes of Action for Mucosal Vaccine Adjuvants.
    Aoshi T
    Viral Immunol; 2017; 30(6):463-470. PubMed ID: 28436755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in veterinary vaccine adjuvants.
    Singh M; O'Hagan DT
    Int J Parasitol; 2003 May; 33(5-6):469-78. PubMed ID: 12782048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles of vaccine design-Lessons from nature.
    Zepp F
    Vaccine; 2010 Aug; 28 Suppl 3():C14-24. PubMed ID: 20713252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
    Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
    J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.
    Marciani DJ
    Drug Discov Today; 2003 Oct; 8(20):934-43. PubMed ID: 14554157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systems analysis of human vaccine adjuvants.
    Harandi AM
    Semin Immunol; 2018 Oct; 39():30-34. PubMed ID: 30122362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in aluminum hydroxide-based adjuvant research and its mechanism.
    He P; Zou Y; Hu Z
    Hum Vaccin Immunother; 2015; 11(2):477-88. PubMed ID: 25692535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions.
    Lang R; Schoenen H; Desel C
    Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flagellin as a vaccine adjuvant.
    Cui B; Liu X; Fang Y; Zhou P; Zhang Y; Wang Y
    Expert Rev Vaccines; 2018 Apr; 17(4):335-349. PubMed ID: 29580106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in vaccine adjuvants.
    Schijns VE; Lavelle EC
    Expert Rev Vaccines; 2011 Apr; 10(4):539-50. PubMed ID: 21506650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward precision adjuvants: optimizing science and safety.
    Nanishi E; Dowling DJ; Levy O
    Curr Opin Pediatr; 2020 Feb; 32(1):125-138. PubMed ID: 31904601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
    Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
    Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvants: Classification, Modus Operandi, and Licensing.
    Apostólico Jde S; Lunardelli VA; Coirada FC; Boscardin SB; Rosa DS
    J Immunol Res; 2016; 2016():1459394. PubMed ID: 27274998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging concepts in the science of vaccine adjuvants.
    Pulendran B; S Arunachalam P; O'Hagan DT
    Nat Rev Drug Discov; 2021 Jun; 20(6):454-475. PubMed ID: 33824489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.